Abstract. Trifluridine (FTD)/tipiracil (TPI) plus bevacizumab (Bev) is a promising late‐line treatment in metastatic colorectal cancer (mCRC). Although chemotherapy‐induced neutropenia (CIN) is a well‐known predictor of FTD/TPI efficacy, whether CIN is a predictive marker of efficacy for FTD/TPI + B